In summary, our current studies demonstrated that canagliflozin is a potent and selective SGLT2 inhibitor that lowers RTG, increases UGE, improves glycemic control, improves beta-cell function, reduces body weight, increases fatty acid oxidation, and reduces de novo lipogenesisin rodent models of insulin resistance and T2DM. Here, SLC5A2 is linked to Insulin resistance.